Understanding Monoclonal Antibodies (mAbs)

Monoclonal antibodies (mAbs) are immunoglobulins that exhibit a high level of specificity toward a single antigen or epitope. These antibodies are produced from a single B-cell clone, resulting in identical immunoglobulins with precise binding capabilities.

mAbs Mechanisms of Action

mAbs exert their mechanisms of action by specifically binding to target antigens or epitopes on cells or molecules. This targeted binding can block signaling pathways, interfere with protein-protein interactions, or prevent receptor-ligand interactions, leading to the modulation of cellular function and immune response. mAbs can also be engineered to serve as carriers for delivering therapeutic agents (antibody-drug conjugates; ADCs) directly to target cells, enabling selective and precise treatment delivery. Furthermore, certain monoclonal antibodies can trigger immune-mediated cell toxicity or disrupt tumor blood vessel formation, contributing to the inhibition of tumor growth.

History of Monoclonal Antibody Discovery

The history of monoclonal antibody (mAb) discovery traces back to the 1970s when César Milstein and Georges Köhler developed the hybridoma technology. In 1975, they successfully fused antibody-producing B cells with myeloma cells, creating immortal hybridoma cells capable of producing specific antibodies. In 1985, the anti-CD3 muronamab became the pioneering therapeutic antibody to receive clinical approval for combating acute transplant rejection.

Monoclonal Antibody Development Methods

Hybridoma Technology

The utilization of hybridoma technology is a widely employed approach to produce mAbs. This mAb development process typically includes immunization of animals with the target antigen, isolation of antibody-producing B-cells, fusion of B-cells with myeloma cells to form hybridoma cells, screening and selection of desired antibody-producing hybridomas, and subsequent culturing and harvesting of monoclonal antibodies from the selected hybridoma clones. During the development process, antibody characterization is crucial to assess the quality, potency and specificity of the antibodies.

Phage Display Technique

Phage display is a technique that involves expressing antibody fragments on the surface of bacteriophages. These phages can then be screened for their binding affinity to a specific target antigen, allowing the identification of high-affinity antibodies.

Recombinant Antibody Production

Recombinant antibody production utilizes genetic engineering to create custom antibodies by combining genes from diverse sources, typically obtained from B cells of immunized organisms, allowing the generation of hybrid antibodies with unique characteristics.

Chimeric Antibodies

Chimeric antibodies are composite molecules composed of segments from different species, where specific regions, such as the Fc or constant domains of a mouse monoclonal antibody, can be substituted with the corresponding regions from a human or another species' antibody.

Ensuring Product Quality Attributes

Despite the method of development, monoclonal antibodies can exhibit heterogeneity due to enzymatic and nonenzymatic modifications, such as incomplete disulfide bond formation, glycosylation, N-terminal cyclization, C-terminal lysine processing, deamidation, isomerization, oxidation, and other post-translational modifications. When developing mAbs for therapeutic use, it is important to consider and test for product quality attributes.

Types of Monoclonal Antibodies

Naked Monoclonal Antibodies

• Naked monoclonal antibodies function independently without any attached drugs or radioactive materials, operating solely based on their inherent properties.

Conjugated Monoclonal Antibodies

• Conjugated monoclonal antibodies have been linked or combined with a chemotherapy drug or a radioactive particle.

Bispecific Monoclonal Antibodies

• Bispecific monoclonal antibodies are specialized antibody molecules designed to bind to two different target proteins simultaneously. For instance, blinatumomab binds to the CD19 protein found in certain leukemia and lymphoma cells, and to the CD3 protein present in T cells. This dual binding mechanism brings cancer cells and immune cells together, potentially leading to immune system-mediated attacks on the cancer cells.

Applications of Monoclonal Antibodies

• Monoclonal antibodies serve as indispensable tools in laboratory research and in home-testing kits.
• They are also used in analytics and chemical research, including immunoassays, research tools, protein purification, and drug development – these processes play a critical role in tissue and blood typing.
• mAb therapies can potentially minimize side effects and improve patient outcomes.
• mAbs therapeutic uses also include cancer treatments, autoimmune diseases, infectious diseases, inflammatory disorders and as immunomodulatory agents.

Examples of mAbs in treatment include Rituximab, Trastuzumab, Pembrolizumab, Adalimumab, Bevacizumab, and Eculizumab, which are used for the treatment of various conditions such as cancer, autoimmune diseases, and rare blood disorders.

Future Direction for Monoclonal Antibodies

Cell Line Development

Cell line development plays a crucial role in the future of antibody engineering. It enables the generation of stable cell lines that can produce engineered recombinant antibodies with improved properties, such as enhanced affinity, specificity and stability. However, this process is cumbersome and ripe for automation and innovation targeting process improvements that speed up development and manufacturing while ensuring critical quality attributes are not adversely impacted.

Combination Therapies

Combination therapies are emerging as a promising approach, where monoclonal antibodies are used in combination with other therapies such as chemotherapy, immune checkpoint inhibitors, or targeted small molecules.

Personalized Medicine and Biomarkers

The future of monoclonal antibodies also involves personalized medicine and biomarkers, where specific patient characteristics and biomolecular signatures are utilized to tailor antibody treatments. This approach allows for individualized dosing, treatment selection, and improved patient outcomes.

Novel Applications in Imaging

Furthermore, there is a growing interest in utilizing monoclonal antibodies in novel applications such as imaging. Antibodies can be engineered or conjugated with imaging agents to enable precise disease detection, imaging of specific targets, and monitoring of treatment response, opening new avenues for early diagnosis and therapeutic monitoring.

recent-articles